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1607-551X/Copyright ª 2015, KaohsiuAbstract Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and lethal interstitial lung
disease with unknown etiology. Divergent observations have suggested that genetic factors
contribute to IPF susceptibility. This study investigated the relationship between human leuko-
cyte antigen (HLA), cytokine gene polymorphisms, and IPF in a Chinese Han population. The
gene polymorphisms of HLA-A, -B, -DRB1, tumor necrosis factor alpha [TNF-a (308 A/G)],
transforming growth factor beta [TGF-b1 (þ869 T/C)], interleukin 10 [IL-10 (592 C/A,
819 T/C, and 1082 G/A)], and interferon gamma [IFN-g (þ874 T/A)] were detected in
102 individuals with IPF and 266 unrelated normal controls using PCR with sequence-specific
primers and a high-resolution melt (HRM) approach. The data showed that there was no differ-
ence in HLA allele frequencies between the IPF and control groups. However, the data showed
the frequency of HLA-A*02-DRB1*04 haplotype in the IPF group was significantly higher than
that in the control group [odds ratio (OR) Z 4.69, 95% confidence interval (CI) Z 1.82
e12.08, p < 0.001]. In addition, no differences in the allele and genotype distributions of
the cytokines were found between the IPF and control groups (p > 0.01). Our findings suggest
that there is an association between specific HLA haplotype and IPF genetic susceptibility and
that the genetic variability of some cytokines may not be involved in the pathogenesis of IPF.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Idiopathic pulmonary fibrosis (IPF) is a rare, progressive,
and lethal interstitial lung disease with unknown etiology.
With an incidence of 4.6e10.3/100,000 individuals per year
and no effective drug treatment, the median survival of IPF
patients is only 2e3 years [1]. The evidence-based guide-
lines for the diagnosis and management of IPF published by
the American Thoracic Society, the European Respiratory
Society, the Japanese Respiratory Society, and the Latin
American Thoracic Association (ATS/ERS/JRS/ALAT) in 2011
[2] defined the radiological and histological criteria for
typical interstitial pneumonia more precisely. However, the
pathophysiology of IPF remains poorly understood, and
research into the underlying genetic mechanisms of IPF is
scarce. Even so, the research suggests the genetic factors
may contribute to the development of IPF [3]. Gene mu-
tations in surfactant protein A2 [4], surfactant protein C
[5], and telomerase reverse transcriptase [6] are associated
with the IPF. Recent studies have also demonstrated a
relationship between the mucin 5B gene (MUC5B) promoter
polymorphism and IPF [7,8]. However, the molecular basis
of IPF remains unclear.
Human leukocyte antigen (HLA) is located at chromosome
6p21.31 [9]. HLA constitutes the most complex and highly
polymorphic genetic system in the human genome. A total of
8933 alleles, including 3192 HLA-A, 3977 HLA-B, and 1764
HLA-DRB1 alleles, have been identified at HLA class I and
class II loci in the world according to the ImMunoGeneTics
(IMGT)/HLA database (http://www.ebi.ac.uk/imgt/hla/
stats). The main function of the HLA system is the regula-
tion of the immune response. Patients with immunological
disorders often have an abnormal distribution of HLA alleles
and haplotypes [10,11]. Interestingly, several studies have
shown that people with certain HLA polymorphisms have a
higher susceptibility for IPF [12e14]. However, another study
indicated that HLA is not associated with IPF [15]. Because of
the scarce and conflicting results on the role of HLA in IPF,
further research into this topic is needed.
Immune dysfunction may be involved in the pathology of
IPF [16]. One current hypothesis regarding the primary
pathogenic mechanism for lung fibrosis involves an imbal-
ance between pro- and anti-fibrotic/inflammatory cyto-
kines [17,18]. Tumor necrosis factor alpha (TNF-a) is an
important proinflammatory cytokine and apoptotic mole-
cule, which is one of the earliest cytokines implicated in
the pathogenesis of fibrosing lung disease [19]. Study
showed that TNF-a was significantly elevated in the su-
pernatants of bronchoalveolar lavage (BAL) immune cells of
IPF [20]. Increased apoptosis of alveolar epithelial cells and
impaired apoptosis of myofibroblasts may link the TNF-a to
the pathogenesis of IPF [21]. Interferon gamma (IFN-g) also
is a proinflammatory cytokine and has antifibrotic activ-
ities. IFN-g mediates anti-fibrogenic effects by reducing
fibroblast proliferation, chemotaxis, and collagen produc-
tion [22]. IFN-g was decreased in IPF patients, and the
paucity of IFN-g may favor the development of progressive
fibrosis [23]. Transforming growth factor beta-1 (TGF-b1) is
a potent profibrotic cytokine and may play a central role in
the pathogenesis of pulmonary fibrosis [24]. In IPF patients,
alveolar epithelial cells have profibrotic phenotype byexpressing TGF-b1 which can excessively activate fibro-
blasts [25]. Interleukin 10 (IL-10) is another forcefully
immunosuppressive cytokine. Gene expression analyses
identified that IL-10 was downregulated in IPF [26]. IL-10
may suppress the production and activation of TGF-b1 in
the lung and thus attenuate pulmonary fibrosis [27].
Single nucleotide polymorphisms (SNPs) within promoters
or other regulatory sequences of cytokine genes mainly in-
fluence the production and secretion of proteins. These
polymorphisms include variants in the genes coding for TNF-
a at position 308, TGF-b1 at þ869, IL-10 at 1082, 819,
and 592, and IFN-g at þ874. Study confirms that there is a
significant association of the TNF-a (308 A) allele with IPF
[28]. Several studies suggest that the TGF-b1 geneþ869 T/C
polymorphism may affect susceptibility to IPF [29,30].
Moreover, a novel IL-10 þ43 G/A polymorphism was identi-
fied, which could affect the efficiency of protein trans-
location and signal peptide cleavage resulting in lower levels
of IL-10 protein secretion in IPF [31]. However, no studies
report the correlation between the polymorphisms of IL-10
at 1082, 819, and 592, and IFN-g at þ874 and IPF.
In the present study, 102 IPF patients and 266 controls
were genotyped for HLA-A, B, and DRB1. Moreover, we
evaluated the polymorphisms of TNF-a (308 A/G), TGF-b1
(þ869 T/C), IL-10 (592 C/A, 819 T/C, 1082 G/A), and
IFN-g (þ874 T/A) in these two groups. Our results showed
that some HLA haplotype frequencies were different be-
tween IPF patients and controls, suggesting that IPF may be
associated with specific haplotypes.
Methods
Participants
One hundred and two individuals with IPF were recruited
between August 2005 and September 2014 from the
Department of Thoracic Surgery in Wuxi People’s Hospital
of Nanjing Medical University, Wuxi, P.R. China. All of the
participants were unrelated Han ethnicity recipients of lung
transplantations for end-stage IPF. IPF was diagnosed based
on the official ATS/ERS/JRS/ALAT statement [2]. The
diagnosis is confirmed by the demonstration of a usual
interstitial pneumonia (UIP) pattern in a high-resolution
computed tomography (HRCT) of the lungs, or else histo-
logically by lung biopsy, along with the exclusion of other
causes. The baseline characteristics of the IPF patients are
recorded in Table 1.
Two hundred and sixty six individuals (137 males and 129
females, age, 56.70  12.80 years) from the same ethnicity
and without systemic diseases were enrolled into the study
as controls. No difference in the age or sex distributions
was found between the IPF group and the control group.
This study was approved by the Ethics Committee of the
Wuxi People’s Hospital of Nanjing Medical University, and
all protocols were in accordance with the ethical guidelines
of the 1975 Helsinki Declaration.
DNA extraction
Whole blood samples were collected in anticoagulant tubes
containing EDTA-K2. Genomic DNA was extracted using a
Table 1 The baseline characteristics of the idiopathic
pulmonary fibrosis patients.
Characteristics Values
Age (y) 59.34  9.87
Sex (male/female) 45/57
Han 102 (100)
Weight (kg) 64.8  12.4
Height (cm) 166.8  6.9
Smoking status
Current smoker 0 (0)
Exsmoker 26 (25.49)
Nonsmoker 76 (74.51)
Pulmonary function
FEV1 (% pred) 61.7  18.7
FVC (% pred) 58.1  20.6
FEV1/FVC (%) 84.9  10.5
Exposure history (House dust,
birds, cotton, chemical materials)
None 102 (100)
Yes 0 (0)
System disease (dermatomyositis,
rheumatoid arthritis, sarcoidosis,
lupus & scleroderma)
None 102 (100)
Yes 0 (0)
Data presented as n (%) or mean  standard deviation, unless
otherwise indicated.
FEV1 Z forced expiratory volume in 1 second; FVC Z forced
vital capacity.
HLA, cytokine gene polymorphism and IPF 615genomic DNA purification kit (Promega, Madison, WI, USA)
in accordance with the manufacturer’s instructions.
HLA typing of IPF patients and healthy individuals
The HLA alleles were examined with PROTRANS SSP ABDR
trays (ProTrans, Friesoythe, Niedersachsen, Germany)
following the manufacturer’s instructions. In brief, 280 ml
of Buffer D, 560 mL of Buffer Y, 200 mL of genomic DNA
(75 ng/mL), and 32.5 U Taq DNA polymerase were mixed in a
1.5 mL centrifuge tube; this DNA mastermix was dispensed
into 96-well trays prealiquoted with primers, and amplified
in a Perkin Elmer 9600 thermocycler (Perkin Elmer, Foster
City, CA, USA). Thermocycling conditions were one cycle of
96C for 130 seconds, 63C for 60 seconds, then nine cycles
of 96C for 10 seconds, 63C for 60 seconds, followed by 20
cycles of 96C for 10 seconds, 59C for 50 seconds, and 72C
for 30 seconds. The electrophoresis of the PCR products
was performed in a 2% agarose gel. The results were
interpreted based on the positive amplification bands.
Genotyping of TNF-a (L308 A/G), TGF-b1 (D869 T/
C), IL-10 (L592 C/A, L819-T/C, and L1082 G/A),
and IFN-g (D874 T/A) genes by high resolution
melting assay
The genotyping of the TNF-a (308 A/G), TGF-b1 (þ869 T/
C), IL-10 (IL-10 592 C/A, 819 T/C, and 1082 G/A), andIFN-g (þ874 T/A) gene polymorphisms was performed on a
LightCycler 480 instrument (Roche Applied Science, Basel,
Switzerland) by a high resolution melting (HRM) method.
The primers used for the HRM assay were TNF-a (308 A/G)
forward (5ʹ-AGG CAA TAG GTT TTG AGG GGC AT-3ʹ) and
reverse (5ʹ-GGC GGG GAT TTG GAA AGT T-3ʹ), TGF-b1 (þ869
T/C) forward (5ʹ-GTT CGC GCT CTC GGC AGT-3ʹ) and
reverse (5ʹ-GTA GCC ACA GCA GCG GTA GCA-3ʹ), IL-10 (592
C/A) forward (5ʹ-AAA GGA GCC TGG AAC ACA TCC TGT-3ʹ)
and reverse (5ʹ-AGT TCC CAA GCA GCC CTT CCA TTT-3ʹ), IL-
10 (819 T/C) forward (5ʹ-TTC TCA GTT GGC ACT GGT GT-
3ʹ) and reverse (5ʹ-GTG CTC ACC ATG ACC CCT AC-3ʹ), IL-10
(1082 G/A) forward (5ʹ-CAC ACA CAA ATC CAA GAC AAC A-
3ʹ) and reverse (5ʹ-ATG GAG GCT GGA TAG GAG GT-3ʹ), and
IFN-g (þ874 T/A) forward (5ʹ-ATT CAC AAT TGA TTT TAT
TCT TAC AAC A-3ʹ) and reverse (5ʹ-CGA GCT TTA AAA GAT
AGT TCC AAA CA-3ʹ). The PCR reaction was performed in a
20 mL volume composed of 2.5mM MgCl2, 0.5mM of the
forward and reverse primers, 200mM of each dNTP, 0.5 U of
Taq DNA polymerase (Promega), 1.0 mL of EVAgreen (Bio-
tium, Hayward, CA, USA), and approximately 75 ng of DNA.
The same touchdown PCR program was used for all six
amplicons. The cycling parameters were as follows: initial
DNA denaturation at 95C for 2 minutes, initial annealing at
65C, which was subsequently decreased by 0.5C every
cycle for 20 cycles and held at 55C for 10 seconds for the
next 30 cycles, and, for all cycles, denaturation at 95C for
10 seconds and extension at 72C for 15 seconds. The HRM
was performed at the end of each reaction and consisted of
increasing the temperature from 70C to 99C at intervals
(ramps) of 0.02C/s. The HRM analysis was carried out with
the gene-scanning module (version 1.5) (Roche Applied
Science, Basel, Switzerland).
Statistical analysis
SPSS version 15 (SPSS Inc., Chicago, IL, USA) was used for
the statistical analysis. The frequencies of the cytokine
alleles and genotypes were calculated by direct counting.
Hardy-Weinberg equilibrium (HWE) and HLA allele and
haplotype frequencies were estimated using the Arlequin
program, version 3.5 [32]. Deviations of the cytokine ge-
notype frequencies from HWE were analyzed using a Chi-
square test. The frequency differences for the cytokine
alleles and genotypes and the HLA alleles and haplotypes
between the IPF and control groups were estimated using
the Chi-square test or Fisher’s exact test. Odds ratios (ORs)
and 95% Confidence Intervals (CIs) for relative risk of IPF
were calculated. In this study, only the HLA alleles and
haplotypes with a frequency higher than 2% and 1%,
respectively, were analyzed. All of the reported p values
were two-tailed and a probability value of p < 0.01
was considered as a statistically significant difference.
Results
Analysis of HWE for HLA and cytokine frequencies
in the IPF and control groups
The HWE test for HLA-A, -B, and -DRB1 genotypes revealed
no significant deviation in the IPF group (p Z 0.12,
616 H.-P. Zhang et al.p Z 0.28, and p Z 0.14, respectively) and in the control
group (p Z 0.49, p Z 0.80, and p Z 0.15, respectively).
The genotype distributions of TNF-a (308 A/G), TGF-b1
(þ869 T/C), IL-10 (592 C/A, 819 T/C, 1082 G/A), and
IFN-g (þ874 T/A) also followed HWE (p Z 0.33, p Z 0.55,
p Z 0.19, p Z 0.19, p Z 0.27, and p Z 0.25 in the IPF
group and p Z 0.17, p Z 0.81, p Z 0.06, p Z 0.06,
pZ 0.35, and pZ 0.32 in the control group, respectively).Frequencies of HLA-A, -B, and -DRB1 alleles in the
IPF and control groups
Table 2 shows the frequencies of the HLA-A, -B, and DRB1
alleles in the IPF and control groups. The data showed
that there were no significant differences in the fre-
quencies of HLA alleles between the IPF and control
groups (p > 0.01).Table 2 Allele frequency of human leukocyte antigen (HLA)-A
control participants.
HLA allele IPF (2n Z 204) Control (2n Z 53
n GF (%) n GF
A*01 5 2.45 15 2.
A*02 66 32.35 159 29.
A*03 9 4.41 14 2.
A*11 41 20.10 133 25.
A*24 24 11.76 74 13.
A*26 8 3.92 23 4.
A*30 13 6.37 33 6.
A*33 21 10.29 59 11.
B*07 5 2.51 17 3.
B*13 20 10.87 51 10.
B*15 34 20.00 89 20.
B*27 9 4.62 18 3.
B*35 12 6.25 23 4.
B*38 5 2.51 14 2.
B*40 27 15.25 65 13.
B*44 7 3.55 20 3.
B*46 21 11.48 65 13.
B*51 15 7.94 32 6.
B*52 5 2.51 12 2.
B*54 6 3.03 14 2.
B*55 5 2.51 20 3.
B*58 13 6.81 42 8.
DRB1*01 5 2.45 12 2.
DRB1*03 15 7.35 36 6.
DRB1*04 27 13.24 53 9.
DRB1*07 23 11.27 45 8.
DRB1*08 7 3.43 41 7.
DRB1*09 26 12.75 92 17.
DRB1*11 15 7.35 33 6.
DRB1*12 22 10.78 73 13.
DRB1*13 10 4.90 39 7.
DRB1*14 15 7.35 31 5.
DRB1*15 31 15.20 65 12.
* The p values were considered significant with p value threshold of
CIZ confidence interval; GFZ gene frequency; HLAZ human leukocFrequencies of HLA haplotypes in the IPF and
control groups
Table 3 shows the frequencies of the HLA haplotypes in the
IPF and control groups. The data show the frequency of
HLA-A*02-DRB1*04 haplotype in the IPF group is significantly
higher than that in the control group (p < 0.001). The OR is
4.69 (95% CI Z 1.82e12.08).
Distribution of TNF-a (L308 A/G), TGF-b1 (D869
T/C), IL-10 (L592 C/A, L819-T/C, and L1082 G/
A), and IFN-g (D874 T/A) alleles and genotypes in
the IPF and control groups
The TNF-a, TGF-b1, IL-10, and IFN-g gene polymorphisms
were detected in the IPF and control groups. Tables 4 and 5
show the frequencies of alleles and genotypes of cytokines, -B, and -DRB1 in idiopathic pulmonary fibrosis patients and
2) c2 value p* OR 95% CI
(%)
82 0.076 0.783 0.87 0.31e2.41
89 0.422 0.516 1.12 0.79e1.59
63 1.544 0.214 1.71 0.73e4.01
00 1.963 0.161 0.75 0.51e1.12
91 0.588 0.443 0.83 0.5e1.35
32 0.059 0.808 0.90 0.40e2.05
20 0.007 0.932 1.03 0.53e2.00
09 0.096 0.756 0.92 0.54e1.56
30 0.282 0.595 0.76 0.28e2.09
60 0.008 0.929 1.03 0.59e1.77
09 0.000 0.984 1.00 0.65e1.53
50 0.441 0.507 1.32 0.58e2.98
52 0.791 0.374 1.38 0.67e2.83
70 0.019 0.890 0.93 0.33e2.61
92 0.140 0.709 1.10 0.68e1.77
91 0.045 0.832 0.91 0.38e2.18
92 0.529 0.467 0.82 0.49e1.39
40 0.442 0.506 1.24 0.66e2.34
31 0.025 0.874 1.09 0.38e3.13
70 0.053 0.817 1.12 0.42e2.96
91 0.769 0.380 0.64 0.24e1.74
57 0.494 0.482 0.79 0.42e1.51
26 0.025 0.874 1.09 0.38e3.13
77 0.079 0.779 1.09 0.59e2.04
96 1.630 0.202 1.38 0.84e2.26
46 1.394 0.238 1.38 0.81e2.34
71 4.421 0.035 0.43 0.19e0.96
29 2.266 0.132 0.70 0.44e1.12
20 0.320 0.572 1.20 0.64e2.26
72 1.132 0.287 0.76 0.46e1.26
33 1.400 0.237 0.65 0.32e1.33
83 0.586 0.444 1.28 0.68e2.43
22 1.153 0.283 1.29 0.81e2.04
0.01.
yte antigen; IPFZ idiopathic pulmonary fibrosis; ORZ odds ratio.
Table 3 Haplotype frequency of human leukocyte antigen in idiopathic pulmonary fibrosis patients and control participants.
HLA haplotype IPF (2n Z 204) Control (2n Z 532) c2 value p* OR 95% CI
n HF (%) n HF (%)
A*02-B*46 19 9.31 49 9.21 0.002 0.965 1.01 0.58e1.77
A*11-B*15 13 6.37 44 8.27 0.744 0.389 0.75 0.40e1.43
A*33-B*58 9 4.41 34 6.39 1.050 0.305 0.68 0.32e1.44
A*30-B*13 13 6.37 26 4.89 0.648 0.421 1.32 0.67e2.63
A*02-B*15 6 2.94 24 4.51 0.930 0.335 0.64 0.26e1.59
A*11-B*40 10 4.90 20 3.76 0.492 0.483 1.32 0.61e2.87
A*02-B*40 13 6.37 19 3.57 2.782 0.095 1.84 0.89e3.79
A*02-B*35 5 2.45 11 2.07 0.102 0.750 1.19 0.41e3.47
A*24-B*15 9 4.41 10 1.88 3.759 0.053 2.41 0.96e6.02
A*02-B*51 7 3.43 8 1.50 2.744 0.098 2.33 0.83e6.50
A*11-B*27 5 2.45 7 1.32 1.185 0.276 1.88 0.59e6.01
A*24-B*40 3 1.47 17 3.20 1.660 0.198 0.45 0.13e1.56
A*02-DRB1*09 13 6.37 49 9.21 1.540 0.215 0.67 0.36e1.26
A*11-DRB1*12 7 3.43 33 6.20 2.204 0.138 0.54 0.23e1.23
A*02-DRB1*12 11 5.39 23 4.32 0.382 0.536 1.26 0.60e2.64
A*33-DRB1*13 6 2.94 22 4.14 0.575 0.448 0.70 0.28e1.76
A*11-DRB1*04 7 3.43 21 3.95 0.107 0.743 0.86 0.36e2.07
A*02-DRB1*15 10 4.90 20 3.76 0.492 0.483 1.32 0.61e2.87
A*30-DRB1*07 10 4.90 20 3.76 0.492 0.483 1.32 0.61e2.87
A*33-DRB1*03 6 2.94 17 3.20 0.032 0.859 0.92 0.36e2.36
A*02-DRB1*11 11 5.39 16 3.01 2.373 0.123 1.84 0.84e4.03
A*11-DRB1*15 8 3.92 15 2.82 0.592 0.442 1.41 0.59e3.37
A*24-DRB1*15 8 3.92 12 2.26 1.548 0.213 1.77 0.71e4.39
A*02-DRB1*04 12 5.88 7 1.32 12.227 < 0.001 4.69 1.82e12.08
A*11-DRB1*14 6 2.94 7 1.32 2.245 0.134 2.27 0.75e6.85
A*24-DRB1*09 8 3.92 8 1.50 4.053 0.044 2.67 0.99e7.22
A*11-DRB1*09 3 1.47 27 5.08 4.900 0.027 0.28 0.08e0.93
A*11-DRB1*08 3 1.47 16 3.01 1.385 0.239 0.48 0.14e1.67
A*24-DRB1*14 4 1.96 12 2.26 0.060 0.806 0.87 0.28e2.72
B*13-DRB1*07 13 6.37 25 4.70 0.843 0.358 1.38 0.69e2.75
B*15-DRB1*15 10 4.90 23 4.32 0.115 0.734 1.14 0.53e2.44
B*46-DRB1*09 10 4.90 39 7.33 1.400 0.237 0.65 0.32e1.33
B*58-DRB1*03 8 3.92 21 3.95 0.000 0.987 0.99 0.43e2.28
B*15-DRB1*12 7 3.43 21 3.95 0.107 0.743 0.86 0.36e2.07
B*15-DRB1*14 7 3.43 7 1.32 3.537 0.060 2.66 0.92e7.70
B*40-DRB1*09 7 3.43 17 3.20 0.026 0.872 1.08 0.44e2.64
B*40-DRB1*11 6 2.94 8 1.50 1.633 0.201 1.98 0.68e5.79
B*13-DRB1*12 4 1.96 12 2.26 0.060 0.806 0.87 0.28e2.72
B*15-DRB1*04 4 1.96 15 2.82 0.432 0.511 0.69 0.23e2.10
B*44-DRB1*13 3 1.47 11 2.07 0.282 0.596 0.71 0.20e2.56
B*58-DRB1*13 3 1.47 14 2.63 0.881 0.348 0.55 0.16e1.94
A*02-B*46-DRB1*09 6 4.41 28 1.13 1.804 0.179 0.55 0.22e1.34
A*30-B*13-DRB1*07 9 4.90 19 1.69 0.285 0.594 0.80 0.36e1.80
A*11-B*15-DRB1*12 3 1.47 14 2.63 0.881 0.348 0.55 0.16e1.94
A*33-B*58-DRB1*13 3 1.47 12 2.26 0.455 0.500 0.65 0.18e2.32
A*11-B*15-DRB1*15 3 1.47 11 2.07 0.282 0.596 0.71 0.20e2.56
* The p values were considered significant with p value threshold of 0.01.
CIZ confidence interval; HFZ haplotype frequency; HLAZ human leukocyte antigen; IPFZ idiopathic pulmonary fibrosis; ORZ odds
ratio.
HLA, cytokine gene polymorphism and IPF 617in the IPF and control groups, respectively. The data show
that the frequencies of the alleles and genotypes are not
significantly different between the IPF and control groups
(p > 0.01).Discussion
Molecular genetic studies have provided important insights
into IPF susceptibility. In particular, the association
Table 4 Allele frequencies of cytokines in idiopathic pulmonary fibrosis patients and control participants.
Cytokine Allele IPF Control c2
value
p* OR 95% CI
n % n %
TNF-a-308 G 186 91.18 491 92.29 0.202 0.653 0.87 0.49e1.57
A 18 8.82 41 7.71 0.202 0.653 1.14 0.64e2.05
TGF-b1-869 T 102 50.00 263 49.44 0.021 0.886 1.02 0.74e1.41
C 102 50.00 269 50.56 0.021 0.886 0.98 0.71e1.35
IL-10-592 C 78 38.24 185 34.77 0.903 0.342 1.18 0.84e1.64
A 126 61.76 347 65.23 0.903 0.342 0.85 0.61e1.19
IL-10-819 C 78 38.24 175 32.89 0.903 0.342 1.18 0.84e1.64
T 126 61.76 357 67.11 0.903 0.342 0.85 0.61e1.19
IL-10-1082 G 20 9.80 30 5.64 3.827 0.050 1.80 0.99e3.26
A 184 90.20 502 94.36 3.827 0.050 0.56 0.31e1.01
IFN-g-874 A 184 90.20 473 88.91 0.374 0.541 1.18 0.69e2.02
T 20 9.80 59 11.09 0.374 0.541 0.85 0.49e1.45
* The p values were considered significant with p value threshold of 0.01.
CIZ confidence interval; IFNZ interferon; ILZ interleukin; IPFZ idiopathic pulmonary fibrosis; ORZ odds ratio; TGFZ transforming
growth factor; TNF Z tumor necrosis factor.
Table 5 Genotype frequencies of cytokines in idiopathic pulmonary fibrosis patients and control participants.
Cytokine Genotype IPF Control c2
value
p* OR 95% CI
n % n %
TNF-a-308 G/A 18 17.65 41 15.41 0.226 0.635 1.16 0.63e2.14
G/G 84 82.35 225 84.59 0.226 0.635 0.86 0.47e1.59
A/A 0 0.00 0 0.00 d d d d
TGF-b1-869 T/C 54 52.94 131 49.25 0.368 0.544 1.15 0.73e1.82
T/T 24 23.53 66 24.81 0.107 0.744 0.91 0.53e1.57
C/C 24 23.53 69 25.94 0.307 0.579 0.86 0.5e1.47
IL-10-592 C/C 12 11.76 25 9.40 0.372 0.542 1.26 0.6e2.62
A/A 35 34.31 106 39.85 0.901 0.342 0.79 0.49e1.28
C/A 55 53.92 135 50.75 0.312 0.577 1.14 0.72e1.8
IL-10-819 C/C 12 11.76 25 9.40 0.372 0.542 1.26 0.6e2.62
T/T 35 34.31 106 39.85 0.901 0.342 0.79 0.49e1.28
C/T 55 53.92 135 50.75 0.312 0.577 1.14 0.72e1.8
IL-10-1082 G/G 0 0.00 2 0.75 0.594 0.441 d d
A/A 82 80.39 234 87.97 3.170 0.075 0.57 0.31e1.06
G/A 20 19.61 30 11.28 4.114 0.043 1.89 1.01e3.53
IFN-g-874 A/A 84 82.35 211 79.32 0.505 0.477 1.24 0.69e2.24
T/T 2 1.96 5 1.88 0.009 0.923 1.09 0.2e5.84
A/T 16 15.69 50 18.80 0.595 0.441 0.78 0.42e1.46
* The p values were considered significant with p value threshold of 0.01.
CIZ confidence interval; IFNZ interferon; ILZ interleukin; IPFZ idiopathic pulmonary fibrosis; ORZ odds ratio; TGFZ transforming
growth factor; TNF Z tumor necrosis factor.
618 H.-P. Zhang et al.between HLA genes and the relative risk for IPF has been
investigated in several populations. However, studies on
the possible role of HLA in IPF susceptibility are fewer and
with contradictory findings [12e14,33]. The contradictory
results may be attributed to the different ethnic and heri-
tage backgrounds of the study populations [34]. Therefore,
this study extensively explored the association between
HLA gene polymorphisms and IPF in a Chinese Han popula-
tion. The data show that there is no difference in the HLA
allele frequencies between the IPF group and control
group. However, the frequency of HLA-A*02-DRB1*04
haplotype is significantly higher in the IPF group than thecontrol group (p < 0.001). Our findings indicate that the
HLA-A*02-DRB1*04 haplotype may confer IPF susceptibility
in this Chinese Han population. One of the challenges of
HLA research is defining the functionality of this haplotype.
Therefore, it is necessary to explore the functions of the
HLA-A*02-DRB1*04 haplotype in IPF.
In addition, a study by Zhang et al [13] showed that HLA-
A*3, B*14, B*15, and B*40 were more prevalent in IPF pa-
tients from the same racial group. However, the present
study did not validate any of these alleles. Therefore, we
compared the data of the IPF groups in two studies. We
found the frequencies of these alleles in the present study
HLA, cytokine gene polymorphism and IPF 619were higher than those in Zhang et al’s [13] report or similar
to them. However, when the data of the control groups
were compared, we found noticeable differences in these
allele frequencies: 1.0%, 0.1%, 1.1%, and 0.8%, respectively
in Zhang et al’s [13] report, and 2.63%, 0.29%, 20.09%, and
13.92%, respectively, in the present study. To investigate
the cause of the differing control results between these
two studies, which were conducted in the same racial
group, we reviewed the relative literatures. Three studies
reported the average allele frequencies of HLA-A*3, B*14,
B*15, and B*40 were 3.18, 0.36, 13.00, and 14.76 respec-
tively from a total of 17,533 Chinese Han donors [35e37].
Obviously, these allele frequencies are high in the normal
Chinese population, but not so low in Zhang et al’s [13]
report, especially in regards to the HLA-B*15 and B*40 al-
leles. We speculate that this is the reason why our results
did not corroborate the findings of Zhang et al [13].
Because the number of HLA alleles is large, sample size
may also have impacted our results. For HLA loci, most
populations exhibit a high number of low-frequency alleles;
thus, the frequency distributions of all the HLA alleles may
have been inaccurately estimated due to the small sample
size of our study. However, because IPF is a rare disease, it
took 11 years to enroll 102 IPF patients who had undergone
lung transplantation in this study. Therefore, we only
analyzed the alleles and haplotypes for which the fre-
quencies in two groups were higher than 2% and 1%,
respectively. Even so, we should take care when drawing
conclusions from our results. Future studies involving larger
samples are required.
Although IPF pathogenesis is not thoroughly understood,
the imbalance between pro- and anti-fibrotic/inflammatory
cytokines is thought to be involved in the main pathogenic
mechanisms of pulmonary fibrosis [27,29]. Single nucleotide
polymorphisms within the promoter of cytokine genes
mainly influence the production of cytokine proteins, which
determine the function of inflammatory and immune me-
diators [38,39]. Gene polymorphisms of cytokines related
to mediators that influence fibrosis/inflammation may be
good candidates for the pathogenesis of IPF. In this study,
we investigated the correlations of the TNF-a (308 A/G),
TGF-b1 (þ869 T/C), IL-10 (592 C/A, 819 T/C, 1082 G/
A), and IFN-g (þ874 T/A) SNPs with IPF. Our results showed
the allele and genotype distribution of cytokines has no
significant difference between the IPF and control groups.
The data suggest the polymorphisms of these cytokines are
not correlated with the etiology of IPF. In spite of this, we
find the frequency of IL-10-1082 G/A genotype has an
increasing trend in the IPF group (p < 0.05). Considering the
relatively small sample size, it needs further research on
the cytokine gene polymorphisms in IPF susceptibility.
In summary, our findings suggest an association of the
HLA-A*02-DRB1*04 haplotype with genetic susceptibility for
IPF. Our results also show that the genetic variability of
cytokines may not be involved in the pathogenesis of IPF.Acknowledgments
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